North America Benign Prostatic Hyperplasia Therapeutics Market Size, Share & Industry Trends Analysis Report By Therapy (Mono Drug Therapy and Combination Drug Therapy), By Therapeutics Class, By Country and Growth Forecast, 2021 - 2027

North America Benign Prostatic Hyperplasia Therapeutics Market Size, Share & Industry Trends Analysis Report By Therapy (Mono Drug Therapy and Combination Drug Therapy), By Therapeutics Class, By Country and Growth Forecast, 2021 - 2027

The North America Benign Prostatic Hyperplasia Therapeutics Market would witness market growth of 3.4% CAGR during the forecast period (2021-2027).

The condition in which the prostate and surrounding tissue enlarge, it is known as benign prostatic hyperplasia (BPH). As a man gets older, his prostate goes through two major growth stages. The first is when the prostate expands in size throughout puberty. The second phase begins around the age of 25 and lasts for the rest of a man's life. When BPH becomes large enough to create issues, it is known as BPH.

Frequent or urgent urination, increased frequency of urination at night (nocturia), trouble commencing urination, weak urine flow or a stream that stops and begins, dribbling at the conclusion of urination, and inability to entirely empty the bladder are all common indications and symptoms of BPH.

According to a report published by the United States Census Bureau in 2018, the number of persons aged 65 and up in the United States is anticipated to rise dramatically between 2016 and 2060. By 2030, one in every five Americans will be 65 or older, accounting for 78.0 million people out of the overall population. This factor the increased geriatric population, this factor would also induce the demand for benign prostatic hyperplasia therapeutics in the region.

The US market dominated the North America Benign Prostatic Hyperplasia Therapeutics Market by Country 2020, and would continue to be a dominant market till 2027; thereby, achieving a market value of $2,411.6 million by 2027. The Canada market is expected to witness a CAGR of 6.5% during (2021 - 2027). Additionally, The Mexico market would experience a CAGR of 5.8% during (2021 - 2027).

Based on Therapy, the market is segmented into Mono Drug Therapy and Combination Drug Therapy. Based on Therapeutics Class, the market is segmented into Alpha Blockers, 5- alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include GlaxoSmithKline PLC (GSK), Astellas Pharma, Inc., Eli Lilly and Company, Allergan PLC (AbbVie), Merck Group (Merck Sharp & Dohme Corp.), Boehringer Ingelheim International GmbH, Teva Pharmaceuticals Industries Ltd., Sanofi S.A., Pfizer, Inc., and Abbott Laboratories.

Scope of the Study

Market Segments covered in the Report:

By Therapy

• Mono Drug Therapy
• Combination Drug Therapy

By Therapeutics Class

• Alpha Blockers
• 5- alpha Reductase Inhibitors
• Phosphodiesterase-5 Inhibitors
• Others

By Country

• US
• Canada
• Mexico
• Rest of North America

Companies Profiled

• GlaxoSmithKline PLC (GSK)
• Astellas Pharma, Inc.
• Eli Lilly and Company
• Allergan PLC (AbbVie)
• Merck Group (Merck Sharp & Dohme Corp.)
• Boehringer Ingelheim International GmbH
• Teva Pharmaceuticals Industries Ltd.
• Sanofi S.A.
• Pfizer, Inc.
• Abbott Laboratories

Unique Offerings from KBV Research

• Exhaustive coverage
• Highest number of market tables and figures
• Subscription based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free